Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.230 -0.190 (-7.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
Via The Motley Fool
This Biotech Stock Could Be the Best Investment of the Decade
There's an incredible growth story hiding in plain sight for investors who can look to the future. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Uncovering Potential: Iovance Biotherapeutics's Earnings Preview
 
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
There are plenty of good ones to choose from, but these three are all undervalued, leaving them ripe for a lot of bullishness sooner than later. 
Via The Motley Fool
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
2 Beaten-Down Stocks With Incredible Upside Potential
Via The Motley Fool
What's Wrong With Iovance Biotherapeutics Stock?
Via The Motley Fool
Where Will Iovance Biotherapeutics Be in 5 Years?
Via The Motley Fool
Is Iovance Biotherapeutics a Millionaire-Maker?
Via The Motley Fool
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month
 
Via Benzinga
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Via The Motley Fool
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
The time to buy quality prospects is when the rest of the market is ignoring their value. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Via The Motley Fool
These stocks are moving in today's after hours session
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
My 3 Favorite Stocks to Buy Right Now
The market's underestimating how well each of these companies should be able to capitalize on their opportunities. 
Via The Motley Fool
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer. 
Via Benzinga
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.